3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape

Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.

Zacks Investment Research • Dec 8, 2025

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

BANGALORE, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112.

Business Wire • Dec 2, 2025

Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds

Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, with North America lagging but Europe and emerging markets offsetting declines through acquisitions and new launches. Key growth drivers include upcoming biosimilar Abatacept and generic GLP-1 drugs, with launches expected to boost earnings beyond FY27 as Revlimid headwinds subside.

Seeking Alpha • Oct 29, 2025

Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues

RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.

Zacks Investment Research • Oct 27, 2025

Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2026 Earnings Call October 24, 2025 10:00 AM EDT Company Participants Richa Periwal - Head of Investor Relations and Analytics Mannam Venkatanarasimham - CFO & Member of the Management Council Erez Israeli - CEO & Member of the Management Council Conference Call Participants Neha Manpuria - BofA Securities, Research Division Damayanti Kerai - HSBC Global Investment Research Bino Pathiparampil - Elara Securities (India) Private Limited, Research Division Saion Mukherjee - Nomura Securities Co. Ltd., Research Division Madhav Marda - Fidelity Investments Kunal Dhamesha - Macquarie Research Tushar Manudhane - Motilal Oswal Securities Limited, Research Division Kunal Randeria - Axis Capital Limited, Research Division Vivek Agrawal - Citigroup Inc., Research Division Harith Mohammed - Spark Institutional Equities Private Limited, Research Division Sumit Gupta - Centrum Broking Limited, Research Division Presentation Operator Good day, and welcome our quarter 2 fiscal year 2026 [indiscernible] Limited.

Seeking Alpha • Oct 24, 2025

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Seeking Alpha • Oct 6, 2025

Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Extrovis AG Bahnhof Park 46340, Baar, Switzerland Media Relations Contact Madhu Marur [email protected]                                          Press Release Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. Baar, Switzerland; August 14, 2025 Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. Food and Drug Administration (USFDA).

GlobeNewsWire • Aug 18, 2025

Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Zacks Investment Research • Jul 24, 2025

India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday.

Reuters • Jul 23, 2025

Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasimham - CFO & Member of the Management Council Richa Periwal - Head of Investor Relations and Analytics Conference Call Participants Abdulkader Puranwala - ICICI Securities Limited, Research Division Aman Vij - Unidentified Company Amey Chalke - JM Financial Institutional Securities Limited, Research Division Bino Joseph Pathiparampil - Elara Securities (India) Private Limited, Research Division Damayanti Kerai - HSBC Global Investment Research Foram Prashant Parekh - BOB Capital Markets Limited, Research Division Harith Mohammed Ahamed - Spark Institutional Equities Private Limited, Research Division Kunal Dhamesha - Macquarie Research Madhav Marda - Unidentified Company Fidelity Investments - Unidentified Company Neha Manpuria - BofA Securities, Research Division Saion Mukherjee - Nomura Securities Co. Ltd., Research Division Shashank Krishnakumar - Emkay Global Financial Services Ltd.

Seeking Alpha • Jul 23, 2025